Literature DB >> 7518839

The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1.

D Hollenbaugh1, L H Wu, H D Ochs, S Nonoyama, L S Grosmaire, J A Ledbetter, R J Noelle, H Hill, A Aruffo.   

Abstract

The molecular origin of X-linked hyper IgM syndrome has recently been identified as a defect in the ligand of CD40, gp39, a protein expressed on the surface of activated T cells. The availability of detailed pedigrees for three families with affected males allowed assessment of the random or nonrandom nature of the inactivation of the defective X chromosome as well as a determination of the origin of the mutation. X chromosome inactivation was studied because of the relevance to the ability to detect carriers of HIGM1 and the potential for phenotypic effect in the carriers. Using immunostaining, PCR, and DNA sequencing, we found that the defective gene for gp39 is not selectively inactivated. Even in the presence of extremely skewed inactivation, normal levels of serum Ig were found. In carriers in which the defective gene is predominantly expressed, staining alone revealed the carrier status reliably while cloning and sequencing of the cDNA was necessary when the normal gene was predominantly expressed. Unlike some other X-linked defects where extreme Lyonization may lead to disease, a small population of cells expressing the wild-type gp39 is sufficient to maintain normal humoral immunity and prevent the clinical symptoms of X-HIM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518839      PMCID: PMC296138          DOI: 10.1172/JCI117377

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling.

Authors:  J Gordon; M J Millsum; G R Guy; J A Ledbetter
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

3.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  B lymphocytes from X-linked agammaglobulinemia. Delayed expression of light chain and demonstration of Lyonization in carriers.

Authors:  J Schwaber; J Payne; R Chen
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

5.  Female haemophilia A in a family with seeming extreme bidirectional lyonization tendency: abnormal premature X-chromosome inactivation?

Authors:  J Ingerslev; M Schwartz; L U Lamm; T A Kruse; A Bukh; S Stenbjerg
Journal:  Clin Genet       Date:  1989-01       Impact factor: 4.438

6.  The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.

Authors:  D L Thiele; P E Lipsky
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

7.  Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).

Authors:  J A Ledbetter; G Shu; M Gallagher; E A Clark
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

8.  Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.

Authors:  F M Uckun; W Jaszcz; J L Ambrus; A S Fauci; K Gajl-Peczalska; C W Song; M R Wick; D E Myers; K Waddick; J A Ledbetter
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes.

Authors:  S Paulie; B Ehlin-Henriksson; H Mellstedt; H Koho; H Ben-Aissa; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Carrier detection in typical and atypical X-linked agammaglobulinemia.

Authors:  M E Conley; J M Puck
Journal:  J Pediatr       Date:  1988-05       Impact factor: 4.406

View more
  18 in total

1.  Phenotypic heterogeneity in a family with a CD40 ligand intracellular domain mutation.

Authors:  S Kiani-Alikhan; P F K Yong; K C Gilmour; D Grosse-Kreul; E G Davies; M A A Ibrahim
Journal:  J Clin Immunol       Date:  2011-10-19       Impact factor: 8.317

Review 2.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.

Authors:  Caroline Y Kuo; Joseph D Long; Beatriz Campo-Fernandez; Satiro de Oliveira; Aaron R Cooper; Zulema Romero; Megan D Hoban; Alok V Joglekar; Georgia R Lill; Michael L Kaufman; Sorel Fitz-Gibbon; Xiaoyan Wang; Roger P Hollis; Donald B Kohn
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

4.  X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome.

Authors:  T J Kipps
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 5.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

6.  Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.

Authors:  K P MacDonald; Y Nishioka; P E Lipsky; R Thomas
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Molecular pathology of the X-linked hyper-immunoglobulin M syndrome: detection of wild-type transcripts in a patient with a complex splicing defect of the CD40 ligand.

Authors:  R Ameratunga; J McKee; J French; R Prestidge; W Fanslow; J Marbrook
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

8.  A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.

Authors:  Q Lin; J Rohrer; R C Allen; M Larché; J M Greene; A O Shigeoka; R A Gatti; D C Derauf; J W Belmont; M E Conley
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  Genomic structure and PCR-SSCP analysis of the human CD40 ligand gene: its application to prenatal screening for X-linked hyper-IgM syndrome.

Authors:  K Seyama; S Kira; K Ishidoh; S Souma; T Miyakawa; E Kominami
Journal:  Hum Genet       Date:  1996-02       Impact factor: 4.132

10.  Somatic mutation of human immunoglobulin V genes in the X-linked HyperIgM syndrome.

Authors:  Y W Chu; E Marin; R Fuleihan; N Ramesh; F S Rosen; R S Geha; R A Insel
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.